Article Sidebar
Views pdf: 54
SOME CASES NON-RESPONSE TO INTRAVITREAL ANTI-VEGF THERAPY IN RETINOPATHY OF PREMATURITY
Main Article Content
Abstract
Retinopathy of prematurity (ROP) is a unique eye disease that exclusively affects premature and low-birth-weight infants. Clinical characteristics include a high-risk population of preterm neonates with associated systemic comorbidities and compromised immune systems, as well as diagnostic challenges due to the limited availability of ophthalmologists specializing in ROP screening, monitoring, and management. Treatment options include primary intervention with intravitreal anti-VEGF injections, a widely adopted and efficacious treatment modality, and secondary intervention with surgical or laser therapy for treatment-resistant cases. It is important to note that despite the effectiveness of anti-VEGF therapy, some patients may exhibit non-responsiveness, necessitating further interventions. This summary is solely for informational purposes and should not be interpreted as a replacement for professional medical advice. Consult a qualified ophthalmologist for comprehensive evaluation and management of ROP in your child
Article Details
Keywords
an-ti VEGF, Retinopathy of prematurity
References
2. Kennedy KA, Mintz-Hittner HA, BEAT-ROP Cooperative Group. Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. J AAPOS Off Publ Am Assoc Pediatr Ophthalmol Strabismus. 2018; 22(1):61-65.e1. doi:10.1016/j.jaapos.2017.10.006
3. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging Off J Int Soc Imaging Eye. 2005;36(4):336-339.
4. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother. 2007;41(4):614-625. doi:10.1345/aph.1H316
5. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5): 391-400. doi:10.1038/ nrd1381
6. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581-611. doi:10.1210/er.2003-0027
7. Fogli S, Del Re M, Rofi E, Posarelli C, Figus M, Danesi R. Clinical pharmacology of intravitreal anti-VEGF drugs. Eye. 2018;32(6): 1010-1020. doi:10.1038/s41433-018-0021-7